Find Funding Opportunities

NIAID announces the availability of funds for administrative supplement awards to promote the development of pediatric chemical research models and medical countermeasures (MCM) discovery under the Chemical Countermeasures Research Program (CCRP). There is currently an unmet need in understanding the natural history, pathophysiology, and treatment of critical illness in infants, children, adolescents, and young adults after exposure to highly toxic DHS-designated Chemicals of Concern (CoCs). The administrative supplement funds are intended to support pilot preclinical projects by CCRP-supported researchers that focus on 1) Basic research to elucidate mechanistic differences in susceptibility to CoCs between pediatric and adult populations and/or 2) Applied research towards the discovery and early development of pediatric-safe MCMs.

The purpose of the NINDS Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic neuroscientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies.

This Notice of Funding Opportunity (NOFO) invites applications for a U54 Specialized Center (henceforth: Consortium) to provide resources, expertise, and coordination to advance innovative, high-quality research on palliative care for those with serious illness across the lifespan. This research infrastructure will encompass Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD), cancer, and other serious illnesses and populations relevant to the partnering Institutes, Centers, and Offices (ICOs). NIH currently funds many palliative care research projects across the ICOs, and there is a need for a structure to leverage synergies, coordinate efforts, develop the scientific workforce, and address remaining gaps in the field. The goals of this initiative include generating new scientific knowledge, in part through supporting pilot and exploratory studies; fostering development of early- and mid-career palliative care investigators; serving as a national platform to provide research resources and facilitate high-quality palliative care research; engaging healthcare systems and community-based organizations as research partners and settings for palliative care research; and disseminating research findings, best practices, data, and other impactful resources to the palliative care research and clinical communities. An important focus of the Consortiums work will be on facilitating research to understand and address disparities in access, quality, and use of palliative care services for health disparities populations or in underserved areas.

This BRAIN Initiative Notice of Funding Opportunity (NOFO) is to scale up efforts for viral, non-viral, transgenic, and gene regulatory element screening technologies and create reagent resources to access brain cell types. This NOFO is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. Reagent development efforts will apply gene transfer, gene regulation, genome engineering, activity sensor/effector, and atlasing technologies for use in both genetically tractable and less tractable systems, including primates and human tissue, which are relevant for future translational efforts. Reagent validation studies will provide feedback to improve scaled resources, informed by deeper understanding of neural gene transfer and regulation mechanisms. Precise targeting could ultimately aid in human disorders, for example, by providing access for gene editors to specific cell types to repair mutations.

This BRAIN Initiative Notice of Funding Opportunity (NOFO) is to support scaled reagent production and distribution facilities involving technologies to access brain cell types. Facilities for production and distribution of these reagents by a broad and diverse set of neuroscientists will be encouraged. This NOFO is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. Efforts will be supported to produce and distribute gene transfer, gene regulation, and genome engineering reagents for use in both genetically tractable and less tractable systems, including primates and human tissue, which are relevant for future translational efforts. Reagents to be produced and distributed are those designed and validated under other NOFOs from the Armamentarium transformative project.

This NOFO would support development and validation of novel clinically- and/or pathophysiologically-relevant human cellular models of ADRD. The cellular model systems would be expected to capture the multi-faceted pathologies and multiple cell types observed in ADRDs. Validation includes internal, face, construct, and predictive (to the extent possible) validation. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Human cellular models need to be novel, complex, and address a gap in the currently available models. Multidisciplinary teams will be highly encouraged. Leveraging the use of and depositing new cells into existing NIH cell repository resources will also be encouraged.

Guided by the goals established in BRAIN 2025: A Scientific Vision and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup, this Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This NOFO encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this NOFO are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.

Guided by the goals established in BRAIN 2025: A Scientific Vision and reinforced by the Advisory Council to the Director Working Group on BRAIN 2.0 Neuroethics Subgroup, this Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This NOFO encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas. Efforts supported under this NOFO are intended to be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Insitute of Neurological Disorders and Stroke R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences, designed to foster the development of physicians as research scientists in areas relevant to the NINDS mission. The research experiences will prepare clinicians to successfully compete for individual NIH mentored career development awards, or where appropriate, independent research awards. This FOA will also support educational activities such that participants of the R25 are expected to attend and participate in an annual workshop specific to this FOA to present their work, discuss progress and plans towards transitioning to the next career stage and to network with other researchers and leaders in their fields. Such success will facilitate their transition from resident/fellow to physician-scientist, and will thus foster retention of a cadre of physician-scientists who will conduct research into the mechanisms of, etiology, and treatment of neurological diseases.

This NOFO would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream and downstream from aggregated protein states to determine what events lead to worse phenotypic outcomes.